Yoshihiko Futamura

Founder at Hinge Therapeutics, Inc.

Health Technology

Profile

Yoshihiko Futamura is the founder of Hinge Therapeutics, Inc. He held the title of Director at the company, and was involved in both founding and business development job functions.

Yoshihiko Futamura active positions

Companies	Position	Start
Hinge Therapeutics, Inc. Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura.	Founder	-

All active positions of Yoshihiko Futamura

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Yoshihiko Futamura's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Hinge Therapeutics, Inc. Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura.	Health Technology